Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1NET 1Gynecologic 1Genitourinary 1Gastrointestinal 1Endocrine 1Breast 1

Conditions

Colorectal Neoplasms 4Gastrointestinal Neoplasms 2Bile Duct Neoplasms 2Vulvar Neoplasms 1Sarcoma 1Prostatic Neoplasms 1Ovarian Neoplasms 1Neuroendocrine Tumors 1Liver Neoplasms 1Hereditary Sensory and Autonomic Neuropathies 1Gallbladder Neoplasms 1Cholangiocarcinoma 1Carcinoma, Neuroendocrine 1Carcinoma, Hepatocellular 1Breast Neoplasms 1Advanced Adult Hepatocellular Carcinoma 1

Interventions

fludarabine 3Vaccines 3Radiotherapy 3Papillomavirus Vaccines 3Nivolumab 3Cyclophosphamide 3pembrolizumab 2entinostat 2aldesleukin 2aflibercept 2Trastuzumab 2Surveys and Questionnaires 2Specimen Handling 2Radiation 2Observation 2Magnetic Resonance Spectroscopy 2Ipilimumab 2CTLA-4 Antigen 2Adoptive Transfer 2trastuzumab deruxtecan 1tivozanib 1tipifarnib 1rocakinogene sifuplasmid 1oncogene protein E7, Human papillomavirus type 16 1nanocis 1durvalumab 1bintrafusp alfa protein, human 1atezolizumab 1Watchful Waiting 1Vorinostat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Vulvar Neoplasms × tivozanib × Gastrointestinal × Clear all
NCT05000294 2026-06-05

Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types

University of Florida

Phase 1/2 Recruiting
29 enrolled
BreastEndocrineGastrointestinalGenitourinaryGynecologicNETSarcoma

Bile Duct Neoplasms, Breast Neoplasms, Gallbladder Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Sarcoma, Vulvar Neoplasms, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡